Delivery Order SPE2DB20D3505-SPE2DB25FYCUD
- Not listed
- The Defense Logistics Agency awarded a $3,418.92 firm fixed-price delivery order to AmerisourceBergen Drug Corp for supply of DUPIXENT 200 mg/1.14 ml pen injectors, with an ultimate completion date of August 12, 2025. This non-set-aside award represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply agreement with DLA Troop Support Medical. The product will be performed at the contractor's location in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a $18,121.68 delivery order to AmerisourceBergen Drug Corp on July 11, 2025, for the supply of DUPIXENT 300 mg/2 ml pen injectable medication in 2 ml quantities. This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 14, 2025. The contract is being performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, and represents a child delivery order under the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 MG/2 ML pen injections with a ceiling value of $4,147.68 under a firm fixed price contract type. The award was made on September 3, 2025, with an ultimate completion date of September 4, 2025, with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location. This delivery order represents a child...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $5,746.28 for DUPIXENT 200 mg/1.14 mL pen injectables on May 30, 2025, with completion scheduled for June 2, 2025. This competitively awarded, firm fixed-price contract involves no set-aside provisions and represents a single delivery order under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The product will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 MG/2 ML pen injectors valued at $7,550.30 under a firm fixed price contract. The award was made on July 21, 2025, with an ultimate completion date of July 22, 2025, and represents a non-set-aside competitive award. AmerisourceBergen will perform this work at its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $8,632.83 to AmerisourceBergen Drug Corp for DUPIXENT 300 MG/2 ML pen injectors (2ML). The contract, executed on August 28, 2025, with completion targeted for August 29, 2025, represents a firm fixed-price delivery order with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfilled this order through competitive procurement processes. This...
- The Defense Logistics Agency awarded a delivery order valued at $6,819.43 to AmerisourceBergen Drug Corp for the supply of DUPIXENT 200 MG/1.14 ML pen injectors on August 6, 2025, with completion expected by August 7, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. DUPIXENT (dupilumab) is a prescription biologic medication used to treat various...
- The Defense Logistics Agency awarded a $4,929.52 delivery order to AmerisourceBergen Drug Corp for DUPIXENT (dupilumab) 300 mg/2 mL pen injections on June 18, 2025, with an ultimate completion date of June 20, 2025. This non-competitive, firm fixed-price delivery order represents a continuation of pharmaceutical supply under AmerisourceBergen's existing contract vehicle with DLA. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,709.46 for Dupixent 300 mg/2 ml pen injections on August 19, 2025. This firm fixed price, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply relationship with DLA. The place of performance is listed as Conshohocken, Pennsylvania, the company's corporate headquarters location. This delivery order falls under AmerisourceBergen's comprehensive...
- The Defense Logistics Agency awarded a $6,995.86 delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of DUPIXENT 300 MG/2 ML pen injectors (2 ML). This is a firm fixed price, non-set-aside contract with an ultimate completion date of September 19, 2025, and performance to be executed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support...
- SPE2DB20D3505Indefinite Delivery Contract
- SPE2DB20D3505-SPE2DB25FYCUDDelivery Order
The Defense Logistics Agency awarded a $26,840.77 delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 MG/2 ML pen injectors on September 24, 2025, with completion scheduled for September 25, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The pharmaceutical products will be performed at the company's corporate headquarters in Conshohocken, Pennsylvania. This delivery order falls within AmerisourceBergen Drug Corp's extensive federal medical supply portfolio, which encompasses a diverse range of pharmaceuticals and medical commodities supporting military healthcare systems. The company maintains a $999,999,999.00 prime IDC with DLA Troop Support Medical (designated SPE2DX) extending through December 2026, which serves as the overarching contract vehicle for supplying pharmaceutical products globally to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. DUPIXENT is a biologic treatment commonly prescribed for atopic dermatitis, eosinophilic esophagitis, and moderate-to-severe eosinophilic asthma, reflecting the breadth of specialty medications that AmerisourceBergen provides to federal military and veteran healthcare programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $26.8k | 9/24/25 |